• 1
    Polascik TJ, Oesterling JE, Partin AW. Prostate specific antigen: a decade of discovery – what we have learned and where we are going. J. Urol. 1999; 162: 293306.
  • 2
    Benson MC, Whang IS, Pantuck A et al. Prostate specific antigen density: a means of distinguishing benign prostatic hypertrophy and prostate cancer. J. Urol. 1992; 147: 81516.
  • 3
    Carter HB, Pearson JD. PSA velocity for the diagnosis of early prostate cancer. A new concept. Urol. Clin. North Am. 1993; 20: 66570.
  • 4
    Oesterling JE, Jacobsen SJ, Chute CG. Serum prostate-specific antigen in a community-based population of helathy men: establishment of age-specific reference ranges. JAMA 1993; 270: 8606.
  • 5
    Catalona WJ, Southwick PC, Slawin KM et al. Comparison of percent free PSA, PSA density, and age-specific PSA cutoffs for prostate cancer detection and staging. Urology 2000; 56: 25560.
  • 6
    Nixon RG, Brawer MK. Enhancing the specificity of prostate-specific antigen (PSA): an overview of PSA density, velocity and age-specific reference ranges. Br. J. Urol. 1997; 79 (Suppl. 1): 617.
  • 7
    Stephan C, Jung K, Lein M, Sinha P, Schnorr D, Loening SA. Molecular forms of prostate-specific antigen and human kallikrein 2 as promising tools for early diagnosis of prostate cancer. Cancer Epidemiol. Biomarkers Prev. 2000; 9: 113347.
  • 8
    Lilja H, Christensson A, Dahlen U et al. Prostate-specific antigen in serum occurs predominantly in complex with alpha 1-antichymotrypsin. Clin. Chem. 1991; 37: 161825.
  • 9
    Stenman UH, Leinonen J, Alfthan H, Rannikko S, Tuhkanen K, Alfthan O. A complex between prostate-specific antigen and alpha 1-antichymotrypsin is the major form of prostate-specific antigen in serum of patients with prostatic cancer: assay of the complex improves clinical sensitivity for cancer. Cancer Res. 1991; 51: 2226.
  • 10
    Catalona WJ, Partin AW, Slawin KM et al. Use of the percentage of free prostate-specific antigen to enhance differentiation of prostate cancer from benign prostatic disease: a prospective multicenter clinical trial. JAMA 1998; 279: 15427.
  • 11
    Roehl KA, Antenor JA, Catalona WJ. Robustness of free prostate specific antigen measurements to reduce unnecessary biopsies in the 2.6 to 4.0 ng./ml. range. J. Urol. 2002; 168: 9225.
  • 12
    Li W, Ren Y, Mee V, Wong PY. Prostate-specific antigen ratio correlates with aggressiveness of histology grades of prostate cancer. Clin. Biochem. 1999; 32: 317.
  • 13
    Morote J, Encabo G, De Torres IM. Use of percent free prostate-specific antigen as a predictor of the pathological features of clinically localized prostate cancer. Eur. Urol. 2000; 38: 2259.
  • 14
    Southwick PC, Catalona WJ, Partin AW et al. Prediction of post-radical prostatectomy pathological outcome for stage T1c prostate cancer with free prostate specific antigen: a prospective multicenter clinical trial. J. Urol. 1999; 162: 134651.
  • 15
    Bangma CH, Kranse R, Blijenberg BG, Schröder FH. The free-to-total serum prostate specific antigen ratio for staging prostate carcinoma. J. Urol. 1997; 157: 5447.
  • 16
    Haese A, Graefen M, Steuber T et al. Total and Gleason grade 4/5 cancer Volumes are major contributors of human kallikrein 2, whereas free prostate specific antigen is largely contributed by benign gland Volume in serum from patients with prostate cancer or benign prostatic biopsies. J. Urol. 2003; 170: 226973.
  • 17
    Henricks WH, England BG, Giacherio DA, Oesterling JE, Wojno KJ. Serum percent-free PSA does not predict extraprostatic spread of prostate cancer. Am. J. Clin. Pathol. 1998; 109: 5339.
  • 18
    Miyake H, Sakai I, Harada K, Hara I, Eto H. Preoperative prediction of final pathological features is not improved by the free-to-total prostate-specific antigen ratio in Japanese men with clinically localized prostate cancer. Int. J. Urol. 2005; 12: 1826.
  • 19
    Diamandis EP, Yousef GM, Clements J et al. New nomenclature for the human tissue kallikrein gene family. Clin. Chem. 2000; 46: 18558.
  • 20
    Becker C, Piironen T, Pettersson K et al. Discrimination of men with prostate cancer from those with benign disease by measurements of human glandular kallikrein 2 (HK2) in serum. J. Urol. 2000; 163: 31116.
  • 21
    Kwiatkowski MK, Recker F, Piironen T et al. In prostatism patients the ratio of human glandular kallikrein to free PSA improves the discrimination between prostate cancer and benign hyperplasia within the diagnostic ‘gray zone’ of total PSA 4–10 ng/mL. Urology 1998; 52: 3605.
  • 22
    Magklara A, Scorilas A, Catalona WJ, Diamandis EP. The combination of human glandular kallikrein and free prostate-specific antigen (PSA) enhances discrimination between prostate cancer and benign prostatic hyperplasia in patients with moderately increased total PSA. Clin. Chem. 1999; 45: 19606.
  • 23
    Partin AW, Catalona WJ, Finlay JA et al. Use of human glandular kallikrein 2 for the detection of prostate cancer: preliminary analysis. Urology 1999; 54: 83945.
  • 24
    Becker C, Noldus J, Diamandis E, Lilja H. The role of molecular forms of prostate-specific antigen (PSA or hK3) and of human glandular kallikrein 2 (hK2) in the diagnosis and monitoring of prostate cancer and in extra-prostatic disease. Crit Rev. Clin. Lab. Sci. 2001; 38: 35799.
  • 25
    Karazanashvili G, Abrahamsson PA. Prostate specific antigen and human glandular kallikrein 2 in early detection of prostate cancer. J. Urol. 2003; 169: 44557.
  • 26
    Stephan C, Jung K, Sinha P. Tumor markers for prostatic cancer – which way in this millennium? Res Adv in Cancer 2002; 2: 14757.
  • 27
    Schedlich LJ, Bennetts BH, Morris BJ. Primary structure of a human glandular kallikrein gene. DNA 1987; 6: 42937.
  • 28
    Recker F, Kwiatkowski MK, Piironen T et al. Human glandular kallikrein as a tool to improve discrimination of poorly differentiated and non-organ-confined prostate cancer compared with prostate-specific antigen. Urology 2000; 55: 4815.
  • 29
    Nam RK, Diamandis EP, Toi A et al. Serum human glandular kallikrein-2 protease levels predict the presence of prostate cancer among men with elevated prostate-specific antigen. J. Clin. Oncol. 2000; 18: 103642.
  • 30
    Bangma CH, Wildhagen MF, Yurdakul G, Schroder FH, Blijenberg BG. The value of (−7, −5) pro-prostate-specific antigen and human kallikrein-2 as serum markers for grading prostate cancer. BJU Int. 2004; 93: 7204.
  • 31
    Haese A, Becker C, Noldus J et al. Human glandular kallikrein 2: a potential serum marker for predicting the organ confined versus nonorgan confined growth of prostate cancer. J. Urol. 2000; 163: 14917.
  • 32
    Haese A, Graefen M, Steuber T et al. Human glandular kallikrein 2 levels in serum for discrimination of pathologically organ-confined from locally-advanced prostate cancer in total PSA-levels below 10 ng/ml. Prostate 2001; 49: 1019.
  • 33
    Haese A, Graefen M, Becker C et al. The role of human glandular kallikrein 2 for prediction of pathologically organ confined prostate cancer. Prostate 2003; 54: 1816.
  • 34
    Black MH, Magklara A, Obiezu CV, Melegos DN, Diamandis EP. Development of an ultrasensitive immunoassay for human glandular kallikrein with no cross-reactivity from prostate-specific antigen. Clin. Chem. 1999; 45: 7909.
  • 35
    Meyer A, Jung K, Lein M, Rudolph B, Schnorr D, Loening SA. Factors influencing the ratio of free to total prostate-specific antigen in serum. Int. J. Cancer 1997; 74: 6306.
  • 36
    Darson MF, Pacelli A, Roche P et al. Human glandular kallikrein 2 (hK2) expression in prostatic intraepithelial neoplasia and adenocarcinoma: a novel prostate cancer marker. Urology 1997; 49: 85762.
  • 37
    Darson MF, Pacelli A, Roche P et al. Human glandular kallikrein 2 expression in prostate adenocarcinoma and lymph node metastases. Urology 1999; 53: 93944.
  • 38
    Magklara A, Scorilas A, Stephan C et al. Decreased concentrations of prostate-specific antigen and human glandular kallikrein 2 in malignant versus nonmalignant prostatic tissue. Urology 2000; 56: 52732.
  • 39
    Lintula S, Stenman J, Bjartell A, Nordling S, Stenman UH. Relative concentrations of hK2/PSA mRNA in benign and malignant prostatic tissue. Prostate 2005; 63: 3249.
  • 40
    Klee GG, Goodmanson MK, Jacobsen SJ et al. Highly sensitive automated chemiluminometric assay for measuring free human glandular kallikrein-2. Clin. Chem. 1999; 45: 8006.
  • 41
    Becker C, Piironen T, Kiviniemi J, Lilja H, Pettersson K. Sensitive and specific immunodetection of human glandular kallikrein 2 in serum. Clin. Chem. 2000; 46: 198206.
  • 42
    Haese A, Vaisanen V, Finlay JA et al. Standardization of two immunoassays for human glandular kallikrein 2. Clin. Chem. 2003; 49: 60110.
  • 43
    Blijenberg BG, Wildhagen MF, Bangma CH, Finlay JA, Vaisanen V, Schroder FH. Comparison of two assays for human kallikrein 2. Clin. Chem. 2003; 49: 2437.
  • 44
    Arcangeli CG, Humphrey PA, Smith DS et al. Percentage of free serum prostate-specific antigen as a predictor of pathologic features of prostate cancer in a screening population. Urology 1998; 51: 55864.
  • 45
    Elgamal AA, Cornillie FJ, Van Poppel HP, Van de Voorde WM, McCabe R, Baert LV. Free-to-total prostate specific antigen ratio as a single test for detection of significant stage T1c prostate cancer. J. Urol. 1996; 156: 10427.
  • 46
    Pannek J, Rittenhouse HG, Chan DW, Epstein JI, Walsh PC, Partin AW. The use of percent free prostate specific antigen for staging clinically localized prostate cancer. J. Urol. 1998; 159: 123842.